


1. A compound having formula (I)

1. A compound having formula (I)



and pharmaceutically acceptable salts thereof
wherein

n is 1 or 2;

A is hydrogen, C₁₋₆ alkyl, aryl, -SO₂R¹, -PO(OC₁₋₆ alkyl)₂, -PO(C₁₋₆ alkyl)₂, -CO(C₁₋₆ alkyl), -CO₂R², -(CH₂)_mCO₂H or -(CH₂)_mCO₂(C₁₋₆ alkyl),

wherein

R^1 is hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, aryl, $-(CH_2)_m$ aryl or $-NR_3R^4$

R^2 is C_{1-6} alkyl, C_{3-7} cycloalkyl, aryl, $-(CH_2)_m$ aryl or alkenyl, and

m is 1, 2 or 3,

wherein

aryl is unsubstituted, substituted phenyl or 5-6 membered aromatic heterocyclic ring, and

R³ and R⁴ are independently hydrogen, C₁₋₆ alkyl or C₃₋₇ cycloalkyl;

B is hydrogen;

C and D are both

phenyl unsubstituted or substituted with one or two substituents selected from C₁₋₄ alkyl, C₁₋₄ alkoxy, methylenedioxy, halogen, hydroxy and NR⁴R⁵, or

C₃₋₇ cycloalkyl;

E, F, G, and H are independently CR⁵ or N.

wherein

R⁵ is hydrogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, CF₃, halogen, hydroxy or -NR⁴R⁵; and

I is $-\text{C}(\text{NH})\text{NH}_2$, $-\text{C}(\text{NH}_2)\text{NOH}$, or $-\text{CH}_2\text{NH}_2$.

2. The compound according to claim 1, wherein C and D are both selected from the group consisting of phenyl and cyclohexyl.

3. The compound according to claim 1, wherein I is $-\text{C}(\text{NH})\text{NH}_2$.

4. The compound according to claim 1, wherein I is -C(NH₂)NOH.

5. The compound according to claim 1, wherein I is CH_2NH_2 .

6. The compound according to claim 1, wherein the compound is selected from the group consisting of

N-aminosulfonyl-D-diphenylalanyl-L-prolyl-[(4-amidinophenyl)methyl]amide,
N-aminosulfonyl-D-diphenylalanyl-L-prolyl-[(4-aminomethylphenyl)methyl]amide,
N-aminosulfonyl-D-dicyclohexylalanyl-L-prolyl-[(4-amidinophenyl)methyl]amide,
N-aminosulfonyl-D-diphenylalanyl-L-azetidine-2-carboxyl-[(4-
amidinophenyl)methyl]amide,
N-Aminosulfonyl-D-valinyl-L-prolyl-[(4-amidinophenyl)methyl]amide,
N-aminosulfonyl-D-diphenylalanyl-L-prolyl-(6-amidino-3-picolyl)amide,
N-aminosulfonyl-D-diphenylalanyl-L-prolyl-(6-aminomethyl-3-picolyl)amide,
N-aminosulfonyl-D-dicyclohexylalanyl-L-prolyl-(6-amidino-3-picolyl) amide,
N-aminosulfonyl-D-diphenylalanyl-L-prolyl-(5-amidino-2-picolyl)amide,
N-aminosulfonyl-D-diphenylalanyl-L-prolyl-[(2-amidino-5-pyrimidyl)methyl]amide,
N-aminosulfonyl-D-diphenylalanyl-L-prolyl-[(4-amidino-3-fluorophenyl)methyl]amide,
N-aminosulfonyl-D-diphenylalanyl-L-prolyl-[(4-amidino-2-fluorophenyl)methyl]amide,
N-aminosulfonyl-D-diphenylalanyl-L-prolyl-[(4-amidino-3-
methylphenyl)methyl]amide,
N-aminosulfonyl-D-diphenylalanyl-L-prolyl-[(4-amidino-3-aminophenyl)methyl]amide,
N-aminosulfonyl-D-diphenylalanyl-L-prolyl-[(4-amidino-3-
methoxyphenyl)methyl]amide,
N-t-butoxycarbonyl-D-diphenylalanyl-L-prolyl-[(4-amidinophenyl)methyl]amide,
N-methoxycarbonyl-D-diphenylalanyl-L-prolyl-[(4-amidinophenyl)methyl]amide,
N-propyloxycarbonyl-D-diphenylalanyl-L-prolyl-[(4-amidinophenyl)methyl]amide,
N-benzyloxycarbonyl-D-diphenylalanyl-L-prolyl-[(4-amidinophenyl)methyl]amide,
N-phenyloxycarbonyl-D-diphenylalanyl-L-prolyl-[(4-amidinophenyl)methyl]amide,
N-methoxycarbonyl-D-dicyclohexylalanyl-L-prolyl-[(4-amidinophenyl)methyl]amide,
N-methoxycarbonyl-D-diphenylalanyl-L-azetidine-2-carboxyl-[(4-
amidinophenyl)methyl]amide,
N-methoxycarbonyl-D-diphenylalanyl-L-prolyl-(6-amidino-3-picolyl) amide,
N-methoxycarbonyl-D-dicyclohexylalanyl-L-prolyl-(6-amidino-3-picolyl) amide,
N-methoxycarbonyl-D-diphenylalanyl-L-prolyl-(5-amidino-2-picolyl) amide,
N-methoxycarbonyl-D-diphenylalanyl-L-prolyl-[(2-amidino-5-pyrimidyl)methyl]amide,
N-methoxycarbonyl-D-diphenylalanyl-L-prolyl-[(4-amidino-3-

fluorophenyl)methyl]amide,

N-methoxycarbonyl-D-diphenylalanyl-L-prolyl-[(4-amidino-3-methoxyphenyl)methyl]amide,

N-methoxycarbonyl-D-diphenylalanyl-L-prolyl-[(4-amidino-3-methylphenyl)methyl]amide,

N-acetyl-D-diphenylalanyl-L-prolyl-[(4-amidinophenyl)methyl]amide,

D-diphenylalanyl-L-prolyl-[(4-amidinophenyl)methyl]amide,

N-methylsulfonyl-D-diphenylalanyl-L-prolyl-[(4-amidinophenyl)methyl]amide,

N-benzylsulfonyl-D-diphenylalanyl-L-prolyl-[(4-amidinophenyl)methyl]amide,

N-dimethylaminosulfonyl-D-diphenylalanyl-L-prolyl-[(4-amidinophenyl)methyl]amide,

N-dimethoxyphosphoryl-D-diphenylalanyl-L-prolyl-[(4-amidinophenyl)methyl]amide,

N-dimethylphosphoryl-D-diphenylalanyl-L-prolyl-[(4-amidinophenyl)methyl]amide,

N-carboxymethyl-D-diphenylalanyl-L-prolyl-[(4-amidinophenyl)methyl]amide,

N-carboxymethyl-D-diphenylalanyl-L-prolyl-(6-amidino-3-picolyl)amide,

N-carboxymethyl-D-diphenylalanyl-L-prolyl-[(4-amidino-3-fluorophenyl)methyl]amide,

N-carboxymethyl-D-diphenylalanyl-L-prolyl-[(4-amidino-3-methylphenyl)methyl]amide,

N-(ethoxycarbonyl)methyl-D-diphenylalanyl-L-prolyl-[(4-hydroxyamidinophenyl)methyl]amide, and

N-phenyl-D-diphenylalanyl-L-prolyl-[(4-amidinophenyl)methyl]amide.

7. A method of modulating trypsin-like serine proteases comprising administering to a mammal an effective amount of the compound of claim 1.

8. A method of inhibiting trypsin-like serine proteases comprising administering to a mammal an effective amount of the compound of claim 1.

9. A method of modulating thrombin comprising administering to a mammal an effective amount of the compound of claim 1.

10. A method of inhibiting thrombin comprising administering to a mammal an effective amount of the compound of claim 1.